HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE
ABDELRAHMAN, Y., ELSHEIKH, M., BAKER, A., AHMED, M., ELTOUNY, M., DAWOD, A. (2021). HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE. EKB Journal Management System, 51(2), 411-416. doi: 10.21608/jesp.2021.193330
YASSER O. ABDELRAHMAN; MAZEN M. ELSHEIKH; AMAL SH. BAKER; MOSTAFA SH. AHMED; MAHA A. ELTOUNY; AYMAN G. A. DAWOD. "HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE". EKB Journal Management System, 51, 2, 2021, 411-416. doi: 10.21608/jesp.2021.193330
ABDELRAHMAN, Y., ELSHEIKH, M., BAKER, A., AHMED, M., ELTOUNY, M., DAWOD, A. (2021). 'HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE', EKB Journal Management System, 51(2), pp. 411-416. doi: 10.21608/jesp.2021.193330
ABDELRAHMAN, Y., ELSHEIKH, M., BAKER, A., AHMED, M., ELTOUNY, M., DAWOD, A. HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE. EKB Journal Management System, 2021; 51(2): 411-416. doi: 10.21608/jesp.2021.193330

HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE

Journal of the Egyptian Society of Parasitology
Article 21, Volume 51, Issue 2, August 2021, Page 411-416  XML PDF (743.61 K)
Document Type: Original Article
DOI: 10.21608/jesp.2021.193330
View on SCiNiTO View on SCiNiTO
Authors
YASSER O. ABDELRAHMAN1; MAZEN M. ELSHEIKH1; AMAL SH. BAKER1; MOSTAFA SH. AHMED2; MAHA A. ELTOUNY1; AYMAN G. A. DAWOD1
1Department of Internal Medicine, Hepatogastroenterology and Endoscopy
2Faculty of Medicine, Ain Shams University, Cairo 115656, and Military Medical Academy
Abstract
The Hepatitis C virus (HCV) has a major impact on public health and is thought to be responsible
for 25% of hepatocellular carcinoma (HCC) and 27% of cirrhosis cases worldwide.
Recent direct-acting antivirals (DAAs) for hepatitis C have the potential to reduce this disease
burden, but there are increased worries about HCC incidence in HCV patients receiving
DAAs. This work assessed the HCC incidence in HCV patients treated with DAAs and its relationship < br />to Hepatic Fibrosis Stage.
The study included 400 chronic HCV patients equally divided into two groups: chronic
HCV patients who did not receive anti HCV medication (control group) and chronic HCV patients
who received different DAAs treatment regimens. There was a highly significant difference
between both groups as regards hepatic fibrosis stages before DAAs therapy. The DAA
receiving group had highly statistically advanced hepatic fibrosis when compared to the control
group. After eighteen months of follow up, the DAA receiving group had a significantly
lower incidence of HCC when compared to the control group (5.5% versus 11% respectively,
p-value 0.04).
Keywords
Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Hepatic fibrosis; Direct- acting antivirals (DAAs)
Statistics
Article View: 116
PDF Download: 193